FDA Denies Approval to Summit BLA for Lung Cancer
FDA has issued Summit Therapeutics a complete response letter (CRL) on its BLA for ivonescimab in combination with platinum-containing chemotherapy for treating patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. Ivonescimab is a novel PD-1 x VEGF bispecific antibody.
The CRL states that the BLA cannot be approved in its present form because “FDA determined that substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement,” according to the company. The agency also noted that “the progression-free survival (PFS) benefit in the absence of a statistically significant OS benefit does not support a positive benefit-risk profile in support of approval.”
The submission is based on data from the Phase 3 HARMONi trial, which evaluated ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy in patients with EGFR-mutated, locally advanced or metastatic NSCLC who were previously treated with a 3rd generation EGFR TKI.
In response to the CRL, the company says it is disappointed because HARMONi met its PFS primary endpoint, becoming the first global Phase 3 study of an immunotherapy-based regimen to show a statistically significant PFS improvement in this setting. “The primary PFS analysis was also supported by longer-term follow-up in a post-hoc analysis, which demonstrated a consistent magnitude of benefit with more mature data of western patients,” it adds.
Ivonescimab is described as a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. “By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF,” the company says.